Medical network on April 12 - in the first quarter of 2017 creep through, the listed companies in 2016 annual report disclosure draws to a close, the pharmaceutical giant the transcript from the page. So far, revenue super billions of fourteen, among them, Shanghai pharma continues with super billions of revenue of its smile. And r&d, is hengrui pharmaceutical course, fosun medicine broke out, followed by the second Shanghai pharma, f medicine. 

 

Table 1: revenue super billions profile listed companies (unit: one hundred million yuan) 

 

 

As of April 11, in the domestic pharmaceutical enterprises has released 2016 annual report, revenue super billions of fourteen. Among them, Shanghai pharma coppi, revenue of 120.765 billion yuan, up 14.45% from a year earlier. And most r&d spending is hengrui pharmaceutical, up to 1.184 billion yuan, the second is fosun medicine, Shanghai medicine, the medicine. 

 

Hengrui pharmaceutical: profit growth bright eye R&d clueless 

 

For the pharmaceutical industry, filed a domestic research and development, must be the first time think of hengrui. Hengrui pharmaceutical peremptory has become the domestic medicine companies worthy of research and development of the king. At the same time, because of r&d fist hard, also bright eye hengrui revenue data. According to hengrui pharmaceutical 2016 annual report, its business income is 11.094 billion yuan, a 19.08% year-on-year growth in 2015 and grew well. 

 

Figure 1: hengrui pharmaceutical r&d situation in recent years (unit: ten thousand yuan) 

 

 

Hengrui r&d investment in 1.184 billion yuan in 2016, than rose 32.82% from a year earlier, high amplitude of r&d spending growth is breathtaking. It is reported, hengrui will r&d spending to keep for a long time in revenue accounted for about 10%, the second to none in the listed companies in the pharmaceutical, its level of research and development and achievements is far ahead. 

 

Hengrui is administered in anti-tumor medicine, surgery, anesthesia, contrast, serious illness, and there is no effective treatment for the key research direction in the field of drug, formed a huge product development pipeline. Hengrui innovation mode from the early stages of innovation "me too", "me - better" gradually toward the original innovation, innovation medicine layout is small molecule drugs to macromolecular drugs. So far, hengrui two innovation medicine iresearch yesterday cloth and path for listing. In 2016, the company introduced Japan Oncolys BioPharma soluble tumor adenovirus product development in China. 

 

Table 2: hengrui main product research and development investment 

 

 

Fosun medicine: outbreaks continue r&d output performance in overseas markets 

 

In 2016, fosun pharma business income of 14.629 billion yuan, up 16.02% from 2015. Notable is, fosun medicine in foreign countries or regions to realize operating income of 2.12235 billion yuan, up 25.37% from 2015, income growth overseas country or area to rise further. 

 

This with fosun medicine in recent years, take "endogenous growth and denotative expansion" two-wheel driven strategy. In addition to the outbreak of the overseas market, develops a type of growth, with the development of innovative research and development as the core driving factors, and continue to invest in the advantage of curative effect, conform to modern medicine development orientation of product research and development. 

 

In 2016, fosun pharma r&d (including capitalization) a total of 1.106 billion yuan, up 33.23% from 2015, the drug manufacturing and r&d plate of the r&d investment of 963.14 million yuan, up 38.03% from 2015. 

 

Figure 2: fosun medicine r&d situation in recent years (unit: ten thousand yuan) 

 

 

Throughout in recent years, fosun pharma r&d spending accounted for the proportion of industry revenue, about 1% growth a year. And through continuous high r&d intensity, its innovative products gradually into the harvest. At present, fosun medicine a total of 173 in research projects, clinical, six declaration on 22 clinical, application of 42 listed. It is worth noting that the company list, strong research and development ability, is in the leading position in the domestic, six single resistance in clinical stage, including varieties of blockbuster restructuring mouse chimeric anti CD20 sheet resistance and restructuring the HER2 humanized single resistance have entered clinical phase III, is expected to take the lead in approved listing. 

 

Shanghai pharma: revenue big MAC development maintain high investment 

 

If a number, a leader in the pharmaceutical industry, single from revenue, Shanghai pharma is one of the leading super big MAC. In 2015 after its revenue of billions, high refresh again in 2016, nearly 120.765 billion yuan, for few other drug firms. 

 

Figure 3: Shanghai pharmaceutical r&d situation in recent years (unit: ten thousand yuan) 

 

Compared with 2015, 618 million yuan, 2016 Shanghai pharmaceutical r&d company (not including pilot base construction investment) still maintain a high level, amounted to 671 million yuan, accounting for 5.40% of the total industry sales revenue. 23.12% of these, 23.12% to innovative drug research and development, to research and development of generic drugs, 48.20% in the second development of existing products, 7.91% in generic drug quality and consistency evaluation of curative effect. 

 

2016 Shanghai pharmaceutical research and development to achieve A number of achievements, restructuring of CD20 humanized monoclonal antibody injection, SPH3127, approval documents for clinical SPH1188 11 for injection restructuring the HER2 humanized monoclonal antibody combination, according to the clinical get accepted 17 generic drug approval documents for clinical, five varieties declare production approval documents, traditional Chinese medicine (TCM) A class of new drugs for injection and rui shu Dan phenolic acids A gain for testing cutting statin calcium tablet to get FDA approval number. 

 

At the same time, Shanghai pharma also focus on advancing the quality of generic drugs and curative effect evaluation of consistency, has now completed the first project 70 varieties, determine 15 colleges and research and development company as a technical service provider, set up Shanghai pharmaceutical reference preparation purchaser library, determine the intention of 32 varieties and 10 3 armour hospital in Shanghai with clinical trial cooperation signed a strategic framework agreement. 

 

F medicine: export business steady progress Research and development of overseas flowers 

 

2016 f medicine business income of about 12.3 billion yuan, up 22.65% from a year earlier, increase common. Including, steadily push forward f medicine overseas business, has covered the mature in Europe and America market and South America, southeast Asia, west Africa and other regions, at present, the total has nearly 20 ANDA approval document issued by the American FDA of about 400 product rules of drugs in the United States market sales, narcotics, fertility regulation medicine company has allowed into southeast Asia, Europe; Company was built in the African Mali pharmaceutical factory put into production at the end of 2015, the company's international business has entered into the phase of rapid development. 

 

Figure 4: people f pharmaceutical r&d situation in recent years (unit: ten thousand yuan) 

 

 

In addition to preparation export performance, f medicine research and development also looking overseas. According to the annual report, the person f medicine annual r&d spending $2016 to $502 million, up 24.37% from a year earlier, 4.07% of the revenue. F medicine in research products, home to more than 200 research projects, 21 in the research of new drug project, including 10 7 project approval documents of clinical trials, a project has entered the phase III clinical trials, two projects completed phase II clinical trial; In research products in more than 80 and the United States, which has been declared to the FDA projects with 12 is waiting for ANDA approval. 

 

conclusion 

 

In a great situation now dominated by innovation, pharmaceutical research and development is undoubtedly the pharmaceutical enterprise survival and development of core power in the future. The development of science and technology, policy innovation, create better environment for research and development of drug firms. Throughout the leading pharmaceutical companies, its revenue is proportional to the most of r&d, r&d future become the industry consensus. In the future, research and development direction of domestic pharmaceutical enterprises, the geometry, we shall see. 

 

Source: annual report of listed companies